NO20003767D0 - Monoklonalt antistoff anti-<alfa>v-integrin og dets anvendelse til inhibering av <alfa>v<beta>6-integrinbinding til fibronektin - Google Patents

Monoklonalt antistoff anti-<alfa>v-integrin og dets anvendelse til inhibering av <alfa>v<beta>6-integrinbinding til fibronektin

Info

Publication number
NO20003767D0
NO20003767D0 NO20003767A NO20003767A NO20003767D0 NO 20003767 D0 NO20003767 D0 NO 20003767D0 NO 20003767 A NO20003767 A NO 20003767A NO 20003767 A NO20003767 A NO 20003767A NO 20003767 D0 NO20003767 D0 NO 20003767D0
Authority
NO
Norway
Prior art keywords
alpha
integrin
inhibit
monoclonal antibody
antibody anti
Prior art date
Application number
NO20003767A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003767L (no
Inventor
Simon Goodman
Beate Diefenbach
Francesc Mitjans
Ana Carceller
Elisabet Rosell-Vives
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20003767D0 publication Critical patent/NO20003767D0/no
Publication of NO20003767L publication Critical patent/NO20003767L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20003767A 1998-01-23 2000-07-21 Monoklonalt antistoff anti-<alfa>v-integrin og dets anvendelse til inhibering av <alfa>v<beta>6-integrinbinding til fibronektin NO20003767L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98101108 1998-01-23
PCT/EP1999/000101 WO1999037683A1 (en) 1998-01-23 1999-01-11 MONOCLONAL ANTIBODY ANTI αv-INTEGRIN AND ITS USE TO INHIBIT αvβ6-INTEGRIN ATTACHMENT TO FIBRONECTIN

Publications (2)

Publication Number Publication Date
NO20003767D0 true NO20003767D0 (no) 2000-07-21
NO20003767L NO20003767L (no) 2000-07-21

Family

ID=8231295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003767A NO20003767L (no) 1998-01-23 2000-07-21 Monoklonalt antistoff anti-<alfa>v-integrin og dets anvendelse til inhibering av <alfa>v<beta>6-integrinbinding til fibronektin

Country Status (17)

Country Link
EP (1) EP1049718B1 (xx)
JP (1) JP2002501086A (xx)
KR (1) KR20010034327A (xx)
CN (1) CN1168741C (xx)
AR (1) AR014464A1 (xx)
AT (1) ATE322508T1 (xx)
AU (1) AU2716399A (xx)
BR (1) BR9907218A (xx)
CA (1) CA2319160A1 (xx)
DE (1) DE69930723T2 (xx)
HU (1) HUP0101151A3 (xx)
ID (1) ID27810A (xx)
NO (1) NO20003767L (xx)
PL (1) PL341569A1 (xx)
SK (1) SK10772000A3 (xx)
WO (1) WO1999037683A1 (xx)
ZA (1) ZA99453B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
CA2453403C (en) 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
CN102659946A (zh) 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
HUE025989T2 (hu) 2006-03-21 2016-05-30 Genentech Inc Alfa5béta1-antagonistákat magában foglaló kombinációs terápia
EA200970108A1 (ru) 2006-07-10 2009-12-30 Байоджен Айдек Ма Инк. Композиции и способы для ингибирования роста smad4-дефицитных форм рака
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
PE20091029A1 (es) 2007-09-26 2009-08-19 Genentech Inc Anticuerpos anti-alfa 5 beta 1
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
BRPI1006270B1 (pt) 2009-03-25 2022-08-16 Genentech, Inc Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
JP2013520173A (ja) * 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαvβ8中和抗体
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin

Also Published As

Publication number Publication date
CA2319160A1 (en) 1999-07-29
AU2716399A (en) 1999-08-09
BR9907218A (pt) 2000-10-24
CN1288469A (zh) 2001-03-21
ATE322508T1 (de) 2006-04-15
HUP0101151A3 (en) 2004-06-28
PL341569A1 (en) 2001-04-23
SK10772000A3 (sk) 2001-01-18
CN1168741C (zh) 2004-09-29
ZA99453B (en) 1999-07-21
WO1999037683A1 (en) 1999-07-29
KR20010034327A (ko) 2001-04-25
NO20003767L (no) 2000-07-21
EP1049718A1 (en) 2000-11-08
ID27810A (id) 2001-04-26
DE69930723D1 (de) 2006-05-18
HUP0101151A2 (hu) 2001-08-28
JP2002501086A (ja) 2002-01-15
DE69930723T2 (de) 2006-11-16
EP1049718B1 (en) 2006-04-05
AR014464A1 (es) 2001-02-28

Similar Documents

Publication Publication Date Title
NO20003767L (no) Monoklonalt antistoff anti-&lt;alfa&gt;v-integrin og dets anvendelse til inhibering av &lt;alfa&gt;v&lt;beta&gt;6-integrinbinding til fibronektin
DK0719859T3 (da) Anti-alfa V-integrin monoklonalt antistof
NO20016243L (no) Anti-&lt;alfa&gt;v-&lt;beta&gt;3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
ID22957A (id) Senyawa dan penggunaannya
DK0724543T3 (da) Syntetisk, porøst, krystallinsk MCM-58, dets syntese og anvendelse
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
ID28990A (id) Herbisida-herbisida dengan urea aminofenilsulfonil asilasi
NO20005412L (no) FAP&lt;alfa&gt;-spesifikt antistoff med forbedret fremstilling derav
NO993487L (no) Utgangsbuffer
DE69809639T2 (de) (hydroxyalkyl)harnstoff vernetzer
MX210287B (es) Composicion de cemento con reduccion de contraccion
DE69332401T2 (de) Verbesserte ein- und mehrstufige FIFO-Entwürfe für Datenübertragungssynchronisiereinrichtungen
ID23059A (id) Seterika dan sikat kukus untuk penggunaan dalam bisnis
DE69522296D1 (de) Verbesserter ausgangsdatenpuffer
NO20013013D0 (no) &lt;alfa&gt;v&lt;beta&gt;6-integrininhibitorer
ID16796A (id) ANTIBODI ANTI-FAS REKOMBINAN DAN DNA-nya
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung
NO20020885D0 (no) &lt;alfa&gt;v&lt;beta&gt;3-integrininhibitorer
DK0853593T3 (da) Syntetisk, porøst, krystallinsk MCM-61, dets syntese og anvendelse
NO20016341D0 (no) Inhibitorer for integrinet &lt;alfa&gt;v&lt;beta&gt;6
NO20020886D0 (no) Nye integrin- &lt;alfa&gt;v&lt;beta&gt;3-inhibitorer
FI950082A (fi) Pituusvakautettu uppoumatyyppinen alus
PT979083E (pt) Utilizacao de 1-ar (alqui)il-imidazolin-2-ona para o tratamento de estados de ansiedade e de tensao
ITMI941470A1 (it) Catalizzatore di deidrogenazione e suo impiego
PT1010689E (pt) Ciclo-heptenos substituidos sua sintese e utilizacao

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application